In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 170 for your search:
Drug:  erlotinib hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO18109, NCT00949910

2.

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25478, NCT01230710

3.

Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML27880, 2011-002168-26, NCT01609543

4.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI3199g, NCT00091663

5.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: D-0410, NCT00153803

6.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000453861, GERCOR-C04-2, EU-20565, GERCOR-OPTIMOX3, GERCOR-DREAM- C04-2, GERCOR-OPTIMOX3-TARCEVA, ROCHE-GERCOR-C04-2, NCT00265824

7.

Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: EORTC-55041, EUDRACT-2004-004333-34, NCT00263822

8.

Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000492254, NCCTG-N05C4, N05C4, NCT00362986

9.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over; 18 to 70 in Italy
Sponsor: Other
Protocol IDs: TORCH, 2005-005968-90, NCT00349219

10.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00057, EUDRACT No. 2006-000259-16, NCT00364351

11.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-774-302, 2005-001747-29, NCT00373425

12.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: PA3, CAN-NCIC-PA3, OSI-CAN-NCIC-PA3, CDR0000069020, NCT00026338

13.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Unknown
Age: 18 and over
Sponsor: Other
Protocol IDs: SRSI-HSRL-02-2007, HSRL-02-2007, PROSE, 2007-006299-13, EU-20975, NCT00989690

14.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BR.21, NCT00036647

15.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22162, 2010-018476-24, NCT01183858

16.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: ML 25359, NCT01229813

17.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-A-U302, 2010-022365-10, NCT01244191

18.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KD019-301, NCT01487174

19.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 1200.125, 2011-002380-24, NCT01523587

20.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: ETOP3-12, 2012-001896-35, NCT01652469

21.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000505821, P30CA093373, UCDCC-128, UCDCC-200311717-5, AVENTIS-Z1001055, NCT00390429

22.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000505895, P30CA093373, UCDCC-159, 200412741, UCDCC-200412741-2, NCT00387322

23.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000517090, P30CA093373, UCDCC-177, BMS-4608, BMS-CA225-261, NCT00408499

24.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 0405-2006, NCT00400374

25.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-08164, NCI-2011-03164, 2008C0131, NCCN-C03, NCT00834678
1     
New Search